Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of ATS Medical, Inc. ("ATS Medical" or the "Company") (Nasdaq: ATSI) arising from the Company's announcement of its intent to be acquired by Medtronic Inc. ("Medtronic"). Under the terms of the agreement, ATS Medical shareholders will receive $4.00 in cash for every share of ATS Medical stock they own in a transaction valued at approximately $370 million.

The investigation is focused on potential insider interest in the transaction, as well as the potential unfairness of the consideration to ATS Medical's shareholders and the process by which ATS Medical's Board of Directors considered and approved the transaction. Indeed, at least one analyst set a price target for $5.00 per share, and the merger agreement contains provisions intended to deter competing bids.

If you are interested in discussing your rights as an ATS Medical shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at  This email address is being protected from spam bots, you need Javascript enabled to view it .